The US Food and Drug Administration (FDA) has approved the Onyx Frontier drug-eluting stent (DES) to treat patients with coronary artery disease, the device manufacturer, Medtronic, announced today. The Onyx Frontier shares the same stent platform and clinical indications as the previous generation Resolute Onyx zotarolimus-eluting stent, including the most recent approval for patients at…
